AI Article Synopsis
- Seasonal influenza leads to serious health risks, particularly for adults aged 60 and older, which is why a high-dose quadrivalent vaccine (HDQIV) was developed to enhance protection compared to the standard vaccine (SDQIV).
- A study analyzed the cost-effectiveness of HDQIV versus SDQIV in Belgium, Finland, and Portugal using health outcome data and economic inputs, ultimately showing that HDQIV provides better health outcomes.
- Results indicated that HDQIV is cost-effective in all three countries, with varying incremental cost-effectiveness ratios (ICER) and a high percentage of simulations supporting its economic viability at set willingness-to-pay thresholds.
Article Abstract
Background: Seasonal influenza may result in severe outcomes, resulting in a significant increase of hospitalizations during the winter. To improve the protection provided by the standard dose influenza quadrivalent vaccine (SDQIV), a high-dose vaccine (HDQIV) has been developed specifically for adults aged 60 and older who are at higher risk of life-threatening complications.
Objectives: The aim of this study was to determine the cost-effectiveness of HD QIV SD-QIV in the recommended population of three European countries: Belgium, Finland and Portugal.
Methods: A cost-utility analysis comparing HDQIV SDQIV was conducted using a decision tree estimating health outcomes conditional on influenza: cases, general practitioner and emergency department visits, hospitalizations and deaths. To account for the full benefit of the vaccine, an additional outcome-hospitalizations attributable to influenza-was also evaluated. Demographic, epidemiological and economic inputs were based on the respective local data. HDQIV relative vaccine efficacy SDQIV was obtained from a phase IV efficacy randomized clinical trial. The incremental cost-effectiveness ratios (ICER) were computed for each country, and a probabilistic sensitivity analysis (1,000 simulations per country) was performed to assess the robustness of the results.
Results: In the base case analysis, HDQIV resulted in improved health outcomes (visits, hospitalizations, and deaths) compared to SDQIV. The ICERs computed were 1,397, 9,581, and 15,267 €/QALY, whereas the PSA yielded 100, 100, and 84% of simulations being cost-effective at their respective willingness-to-pay thresholds, for Belgium, Finland, and Portugal, respectively.
Conclusion: In three European countries with different healthcare systems, HD-QIV would contribute to a significant improvement in the prevention of influenza health outcomes while being cost-effective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13696998.2023.2194193 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Status of Sepsis Care in European Hospitals: Results from an International Cross-Sectional Survey.
Am J Respir Crit Care Med
January 2025
University of Medicine and Pharmacy Carol Davila Bucharest, Bucuresti, Romania.
Rationale: Early detection, standardized therapy, adequate infrastructure and strategies for quality improvement should constitute essential components of every hospital's sepsis plan.
Objectives: To investigate the extent to which recommendations from the sepsis guidelines are implemented and the availability of infrastructure for the care of patients with sepsis in acute hospitals.
Methods: A multidisciplinary cross-sectional questionnaire was used to investigate sepsis care in hospitals.
Biomarkers.
Alzheimers Dement
December 2024
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Background: Fluid biomarkers provide a convenient way to predict AD pathophysiology. However, few studies have focused on determining associations with tau neurofibrillary tangle pathology in the early preclinical AD continuum, relevant to prevention strategies.
Methods: Ninety-nine cognitively unimpaired individuals from the ALFA+ cohort with valid F-RO-948 and F-flutemetamol PET, T1-weighted MRI, cognition, CSF, and plasma biomarkers were included.
Alzheimer's Imaging Consortium.
Alzheimers Dement
December 2024
Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain.
Background: Fluid biomarkers provide a convenient way to predict AD pathophysiology. However, few studies have focused on determining associations with tau neurofibrillary tangle pathology in the early preclinical AD continuum, relevant to prevention strategies.
Methods: Ninety-nine cognitively unimpaired individuals from the ALFA+ cohort with valid 18F-RO-948 and 18F-flutemetamol PET, T1-weighted MRI, cognition, CSF, and plasma biomarkers were included.
Microbial production of food lipids using the oleaginous yeast Apiotrichum brassicae.
Food Res Int
January 2025
VTT Technical Research Centre of Finland, Tekniikantie 21, 02044 VTT Espoo, Finland. Electronic address:
Oleaginous yeasts offer a promising sustainable alternative for producing edible lipids, potentially replacing animal and unsustainable plant fats and oils. In this study, we screened 11 oleaginous yeast species for their lipid profiles and identified Apiotrichum brassicae as the most promising candidate due to its versatility across different growth media. A.
View Article and Find Full Text PDFGlobal Challenges in the Access of Endovascular Treatment for Acute Ischemic Stroke (Global MT Access).
Int J Stroke
January 2025
Department of Neurology, Grady memorial Hospital, Emory University, Atlanta, USA.
Background: Mechanical thrombectomy (MT) is the standard of care for eligible acute ischemic stroke (AIS) patients with large vessel occlusion (LVO) since 2015.
Aim: Our aim was to determine the key challenges for MT implementation and access worldwide.
Methods: We conducted an international online survey consisting of 37 questions, distributed through the World Stroke Organization network, and as invited by co-authors between December 2022 and March 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!